Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stake Boosted by Clark Capital Management Group Inc.

Clark Capital Management Group Inc. raised its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 30.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 178,827 shares of the biopharmaceutical company's stock after buying an additional 41,655 shares during the quarter. Clark Capital Management Group Inc. owned about 0.14% of Halozyme Therapeutics worth $8,550,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. D. E. Shaw & Co. Inc. raised its position in shares of Halozyme Therapeutics by 171.2% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock worth $39,750,000 after buying an additional 524,802 shares during the period. EP Wealth Advisors LLC raised its position in Halozyme Therapeutics by 8.5% in the fourth quarter. EP Wealth Advisors LLC now owns 6,769 shares of the biopharmaceutical company's stock valued at $324,000 after purchasing an additional 533 shares during the period. CoreCap Advisors LLC raised its position in Halozyme Therapeutics by 36.6% in the fourth quarter. CoreCap Advisors LLC now owns 15,831 shares of the biopharmaceutical company's stock valued at $757,000 after purchasing an additional 4,242 shares during the period. Centiva Capital LP purchased a new position in Halozyme Therapeutics in the fourth quarter valued at about $643,000. Finally, Brevan Howard Capital Management LP purchased a new position in Halozyme Therapeutics in the fourth quarter valued at about $1,004,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Stock Performance

NASDAQ HALO traded down $1.87 during trading hours on Friday, reaching $65.86. The company's stock had a trading volume of 2,501,725 shares, compared to its average volume of 1,499,455. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The business has a 50-day simple moving average of $61.45 and a 200 day simple moving average of $55.88. Halozyme Therapeutics, Inc. has a 52 week low of $42.01 and a 52 week high of $70.51. The stock has a market cap of $8.14 billion, a PE ratio of 19.20, a PEG ratio of 0.42 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.98 by $0.13. The company had revenue of $264.86 million for the quarter, compared to analysts' expectations of $231.21 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business's revenue for the quarter was up 35.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.79 earnings per share. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HALO has been the topic of several research reports. JPMorgan Chase & Co. raised their target price on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. HC Wainwright restated a "buy" rating and set a $72.00 target price on shares of Halozyme Therapeutics in a research note on Friday, April 25th. Benchmark downgraded Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday. Finally, Wells Fargo & Company lifted their price target on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research note on Wednesday. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $63.78.

Insider Activity

In related news, SVP Michael J. Labarre sold 1,697 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the sale, the senior vice president now owns 173,756 shares of the company's stock, valued at $10,126,499.68. The trade was a 0.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey William Henderson sold 5,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the sale, the director now directly owns 33,611 shares in the company, valued at approximately $1,972,629.59. The trade was a 12.95% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,697 shares of company stock valued at $1,276,552. Insiders own 2.90% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.